Skip to main content
Premium Trial:

Request an Annual Quote

Compugen to Divest Bioccelerator Line to Biocceleration

NEW YORK, July 17 - Compugen intends to sell its Bioccelerator product line to Biocceleration next month in exchange for "certain fixed payments" and future royalty rights. 
 

"By transferring the Bioccelerator product line, we are strengthening Compugen's focus on our two primary commercialization channels: high-end platforms and services that we offer to leading biopharmaceutical companies, and discoveries based on our own internal research," said Mor Amitai, president and CEO of Compugen.

 

According to Compugen, the Bioccelerator line was designed to accelerate similarity searches in nucleotide and protein databases.

Biocceleration is a bioinformatics company established by a group of private investors, and is headed by Simchon Faigler, who co-founded Compugen in 1993.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.